参考文献
[1] 郑荣寿,孙可欣,张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28.
[2] National Comprehensive Cancer Network. (NCCN) Clinical Practice Guidelines in Oncology.Breast Cancer, Version4.2020. https://www.nccn.org/professionals/physician_gls/default.aspx.[3] Christine M Walko, Celeste Lindley. Capecitabine: A Review[J].Clin Ther.2005 ;27(1):23-44.[4] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范[J].中国癌症杂志,2019,29(8):607-680.[5] 马飞教授:晚期乳腺癌卡培他滨维持治疗进展.[EB/OL].[ 2017-10-10].http://www.ioncol.com/article/NewsInfo.aspx?id=2992[6] M E Cazzaniga, L Cortesi , A Ferzi, et al. Metronomic Chemotherapy With Oral Vinorelbine (mVNR) and Capecitabine (mCAPE) in Advanced HER2-negative Breast Cancer Patients: Is It a Way to Optimize Disease Control? Final Results of the VICTOR-2 Study[J].Breast Cancer Res Treat.2016 ;160(3):501-509.[7] Andrew M Wardley, Xavier Pivot, Flavia Morales-Vasquez, et al. Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-positive Metastatic Breast Cancer[J]. J Clin Oncol 2010;28(6):976-83.[8] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南[M]北京: 人民卫生出版社, 2020.[9] Fei Ma, Quchang Ouyang, Wei Li, et al. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study[J].J Clin Oncol .2019 ;37(29):2610-2619.[10] Zefei Jiang, et al. Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study. ASCO 2019 abstract 1001.[11] Cristina Saura,et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. ASCO 2019 abstract 1002.[12] G G Steger, R Greil, A Lang, et al. Epirubicin and Docetaxel With or Without Capecitabine as Neoadjuvant Treatment for Early Breast Cancer: Final Results of a Randomized Phase III Study (ABCSG-24) [J].Ann Oncol,2014,25(2):366-71.[13] Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani. et al.Adjuvant Capecitabine for Breast Cancer After Preoperative Chemotherapy[J].N Engl J Med 2017;376(22):2147-2159. [14] Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen,Riikka Huovinen, et al. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial[J].JAMA Oncol.2017;3(6):793-800.[15] Joyce O'Shaughnessy, Hartmut Koeppen , Yuanyuan Xiao ,et al. Patients With Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine[J]. Clin Cancer Res.2015;21(19):4305-11.[16] Junjie Li, Keda Yu, Da Pang, et al. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial[J].J Clin Oncol.2020;38(16):1774-1784.[17] XI Wang, et al. Phase III trial of metronomic capecitabine maintenance after standardtreatment in operable triple-negative breast cancer (SYSUCC-001). ASCO 2020 abstract 507.